Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
For Healthcare Professionals
Information for Healthcare Professionals Version No: 0.3 Date: March 2023
For Healthcare Professionals
March 2023 This diary is designed to assist with the administration of velmanase alfa. The diary should be kept as a record of when velmanase alfa is administered.
For Healthcare Professionals
Checklist for the prescription, supply or recommendation of Lariam® (mefloquine) for malaria chemoprophylaxis
For Healthcare Professionals
This guide is intended to provide you with information regarding side effects which may be associated with chemoprophylactic use of Lariam® (mefloquine).
For Healthcare Professionals
Pregnancy Prevention Programme guide for HCP's.
For Healthcare Professionals
This leaflet is to highlight the important risks associated with Leflunomide and to emphasize the need for counselling patients about these risks
For Healthcare Professionals
This educational material is intended to minimize several risks identified in the frame of the European risk management plan established for Leflunomide. The most important risks you should be aware of when prescribing Leflunomide include: • Risk of hepatotoxicity, including very rare cases of severe liver injury, which may be fatal. • Risk of hematotoxicity, including rare cases of pancytopenia, leucopenia, eosinophilia and very rare cases of agranulocytosis. • Risks of infections including rare cases of severe uncontrolled infections (sepsis), which may be fatal. • Risk of serious birth defects when administered during pregnancy. Counselling of patients, careful monitoring and following recommendations regarding the wash-out procedure are required to minimise these risks. Complete prescribing information is provided in the approved Summary of Product Characteristics (SmPC) for Leflunomide.
For Healthcare Professionals
In addition to the Summary of Product Characteristics, this leaflet was developed by the marketing authorisation holder to inform you about all delicate issues potentially arising from Leflunomide medac therapy. Counselling patients on important risks associated with Leflunomide medac therapy and appropriate precautions when using the medicine is required.
Leflunomide Patient Leaflet - Patient leaflet containing important safety information for Leflunomide
For Healthcare Professionals
This leaflet is to highlight the most important risks associated with Leflunomide and to emphasize the need for counselling patients about those important risks
For Healthcare Professionals
Prescriber's Guide
For Healthcare Professionals
This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the care of patients treated with Lemtrada (alemtuzumab), to provide further information about the potential serious risks associated with the use of this medicine. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
The card should be provided to patients prior to treatment by the prescribing physician and is designed to alert other HCPs that the patient has been prescribed Lemtrada (alemtuzumab) and includes details on the associated risks of treatment and contact details of the prescriber. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
Describes required initial screening tests, pre-treatment vaccination course, premedication, general health, and pregnancy and contraception checks immediately before treatment and the subsequent monitoring activities. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Lenalidomide Pregnancy Prevention Programme Information for Patients taking Lenalidomide
Lenalidomide Pregnancy Prevention Programme And Information for Healthcare Professionals Prescribing or Dispensing Lenalidomide
Lenalidomide - Information for Patients and Healthcare Professionals
For Healthcare Professionals
It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.
The safe use of lenalidomide is of paramount importance. Adverse events and cases of suspected or confirmed pregnancy or foetal exposure should be immediately reported to Glenmark Pharmaceuticals Europe Ltd. You can also report the event via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
For Healthcare Professionals
This brochure contains the information needed for prescribing and dispensing lenalidomide, including information about the Pregnancy Prevention Programme (PPP). Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.
This brochure should be given to patients receiving treatment with lenalidomide, as it provides important information about the lenalidomide Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking lenalidomide and how to report side effects.
This card should be given to all patients as it reminds patients of the key educational information and risks of treatment with lenalidomide.
For Healthcare Professionals
This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense lenalidomide. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of lenalidomide will only be allowed from pharmacies registered with Glenmark Pharmaceuticals Europe Ltd.
For Healthcare Professionals
A newly completed Prescription Authorisation Form must accompany each lenalidomide prescription to confirm that the patient has been counselled about the teratogenic risk of lenalidomide and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.
For Healthcare Professionals
This checklist is to assist you with counselling a patient before they commence lenalidomide treatment in order to ensure it is used safely and correctly. The Algorithm provides high level steps for prescribing and dispensing of lenalidomide.
For Healthcare Professionals
Woman of Childbearing Potential Treatment Initiation Form must be completed for each woman of childbearing potential prior to the initiation of their lenalidomide treatment. Woman of Non-Childbearing Potential Treatment Initiation Form must be completed for each woman of non-childbearing potential prior to the initiation of their lenalidomide treatment. Male Treatment Initiation Form must be completed for each male patient prior to the initiation of their lenalidomide treatment.
For Healthcare Professionals
Pregnancy Prevention Programme guide for HCP's.
For Healthcare Professionals
Healthcare Professionals involved in the prescribing or dispensing of lenalidomide must read and understand the information contained within this brochure. For complete safety information please refer to the Summary of Product Characteristics (SmPC) for lenalidomide,
Information for Patients taking Lenalidomide. This Brochure Contains Information About Preventing harm to unborn babies If lenalidomide is taken during pregnancy.
For Healthcare Professionals
Lenalidomide Pregnancy Prevention Programme And Information for Healthcare Professionals Prescribing or Dispensing Lenalidomide
Lenalidomide Pregnancy Prevention Programme Information for Patients taking Lenalidomide
Lenalidomide - Information for Patients and Healthcare Professionals
Lenalidomide Adverse Effects reporting form Pregnancy prevention programme
For Healthcare Professionals
Lenalidomide Combined checklist Pregnancy prevention programme
For Healthcare Professionals
Lenalidomide Pharmacy Registration Form Pregnancy Prevention programme
For Healthcare Professionals
Pregnancy Prevention Programme guide for HCP's
For Healthcare Professionals
Lenalidomide pregnancy specific questionnaire
For Healthcare Professionals
Lenalidomide prescription authorisation form
For Healthcare Professionals
Lenalidomide Pregnancy prevention programme, treatment initiation form for males
For Healthcare Professionals
Lenalidomide Pregnancy Prevention programme for Women Of Non child bearing potential
For Healthcare Professionals
Lenalidomide Pregnancy prevention programme Treatment Initiation form - Women Of Child Bearing Potential
For Healthcare Professionals
Lenalidomide Pregnancy Prevention Programme and information for HCPs prescribing or dispensing Lenalidomide
Lenalidomide Pregnancy Prevention Programme: information for patients taking Lenalidomide
For Healthcare Professionals
Information for Healthcare Professionals Prescribing or Dispensing Lenalidomide: This guide contains the info needed for the prescribing and dispensing of lenalidomide, including information about the Pregnancy Prevention Programme and important safety information. This guide ensures you know what to do before prescribing and dispensing lenalidomide. If lenalidomide is taken during pregnancy it is expected to cause severe birth defects or death to an unborn baby. This Programme is designed to make sure that unborn babies are not exposed to lenalidomide. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals (HCPs) ensure that they have read and understood the Healthcare Professionals Information guide before prescribing or dispensing lenalidomide for any patient. You must ensure that your patients fully understand what you have told them about lenalidomide and that they have completed the Treatment Initiation Form, before starting treatment.
This brochure contains information about: - Preventing harm to unborn babies. If lenalidomide is taken during pregnancy it is expected to cause severe birth defects or death to an unborn baby. - The Lenalidomide Pregnancy Prevention Programme, designed to ensure that unborn babies are not exposed to Lenalidomide. It will provide you with information about what to expect from your treatment, and explain the risks and your responsibilities. - Lenalidomide passes into men’s semen, and is expected to cause severe birth defects or death to an unborn baby. So there is a risk if you have unprotected sex with a woman who can become pregnant. - This brochure will help you understand what to do before, during and after taking lenalidomide. For your own health and safety, please read this brochure as well as the Package Leaflet that comes with your medicine, carefully. If you do not understand something, please ask your prescriber for further explanation.
Contains safety information regarding the risks to an unborn baby from Lenalidomide. Has information for the HCP to complete regarding treatment details and patient specifics (are they male or female, are they receiving counselling, contraception use). Contains emergency contact details.
For Healthcare Professionals
Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of Thromboembolism.
This is a bit more information about the recommendations of combined hormonal contraceptives, in particular the risk of blood clots. Includes key points to bear in mind.
Important information for women about the risk of blood clots with the combined hormonal contraceptives.
For Healthcare Professionals
Levetiracetam overdose can lead to serious adverse event. With every prescription, physicians and pharmacists should advise the patient and/or caregiver on how to measure the prescribed dose
An aide-mémoire for pharmacists dispensing Librachrom to ensure the unique features of the product are explained to patients.
For Healthcare Professionals
Instructions for Pharmacists supplying Levonelle One Step 1500 microgram tablet as emergency contraception
For Healthcare Professionals
Levonorgestrel emergency contraception: important information for women taking other medicines
For Healthcare Professionals
Advice for women taking Levonorgestrel tablets Levonorgestrel 1.5mg Tabletsl PL35507-0126
For Healthcare Professionals
Checklist for Pharmacists Levonorgestrel 1.5mg Tablets PL 35507-0126
For Healthcare Professionals
Levonorgestrel emergency contraception: important information for women taking other medicines. Some medicines or herbal remedies that contain the ingredient St. John's wort, might reduce how well levonorgestrel emergency contraception works. Tell the doctor, pharmacist or nurse if you are currently taking a medicine to treat any of the following, or if you have used one in the past 4 weeks: epilepsy, tuberculosis, HIV, a fungal infection, or if you have taken any herbal remedies that contain the ingredient St. John's wort.
Levonorgestrel emergency contraception: important information for women taking other medicines.
For Healthcare Professionals
Instructions for Pharmacists supplying Postinor 1500 microgram tablet as emergency contraception
For Healthcare Professionals
This educational brochure is intended to minimise the risk of application errors due to confusion of different types of IUS and to reduce the risk of ectopic pregnancies.
For Healthcare Professionals
UK Essential information for the supply of Liberize (sildenafil)
For Healthcare Professionals
UK Liberize (sildenafil) Pharmacy Checklist
Important safety information to minimise the risks of immune-mediated adverse reactions. This Patient Alert Card will help you identify and report side effects from your treatment with cemiplimab.
Important safety information to minimise complications from immune-mediated adverse reactions. This Patient Guide will help you identify and report side effects from your treatment with cemiplimab.
For Healthcare Professionals
Prescriber guide to provide a checklist for assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan
Every patient prescribed Lixiana will receive a Patient Alert Card in the medication pack. This will inform doctors, dentists, pharmacists and other healthcare professionals about the patient’s anticoagulation treatment, along with emergency contact details. Encourage patients to have this card with them at all times and to show it to healthcare professionals prior to any consultation or procedure. Patients should be reminded of the importance of compliance to their treatment regimen, the need to watch for signs and symptoms of bleeding and when to seek medical advice. Patient Alert Cards are available from [email protected] or by calling 08000285122.
For Healthcare Professionals
This risk minimisation material has been developed for Lixiana for all indications. Please ensure that you are familiar with this material as it contains important safety information. In particular, it is aimed at increasing awareness about the potential risk of bleeding during treatment with Lixiana and providing guidance on how to manage that risk.
For Healthcare Professionals
Please use this checklist in conjunction with the SPC during combined hormonal contraceptives consultations. Risk of thromboembolism.
This is more information on recommendations of safety of combined hormonal contraceptives, in particular the risk of blood clots.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers
Combined hormonal contraceptives: Q&As about the important information for women.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
For Healthcare Professionals
Combined Hormonal Contraceptives - checklist for prescribers
Combined hormonal contraceptives: Q&As about the important information for women.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
For Healthcare Professionals
Healthcare professional guide contains information on the serious risks associated with Lojuxta and how to help mitigate these risks.
The purpose of the patient alert card is to inform health care professionals of potential drug-drug interactions before any additional medicinal product is taken. Patients will be instructed to carry this card and show it to all doctors and pharmacists involved in their treatment.
Patient care guide containing important safety information for patients treated with Lojuxta (lomitapide).
For Healthcare Professionals
Direct Healthcare Professional Communication Hydrochlorothiazide: Risk of non‐melanoma skin cancer
For Healthcare Professionals
The prescriber should inform the patients taking hydrochlorothiazide (HCTZ) containing medicines of the risk of non-melanoma skin cancer. Patients should be advised to limit the exposure to sunlight and UV rays and use adequate protection when exposed to sunlight and UV rays to minimise the risk of skin cancer
For Healthcare Professionals
To support the Healthcare Professional in conducting effective, patient-specific, clinical consultations on contraception, and enable them to appropriately supply Lovima® 75 microgram film-coated tablets (desogestrel).
For Healthcare Professionals
• Use of this checklist is optional and this consultation checklist is provided to act as a reminder for pharmacists. • It covers the key considerations when determining suitability of Lovima 75 microgram film-coated tablets for women who request them and advice to provide when supply is made.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD). An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV)secondary to pathological myopia. An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO). An audio version is available on eMC.
A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to retinal vein occlusion (RVO). An audio version is available on eMC.
For Healthcare Professionals
Checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
Important information for women about risk of blood clots with combined hormonal contraceptives (CHC).
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
Patient card to track treatment and provide useful contact details
Patient information leaflet size A4
For Healthcare Professionals
Pharmacy manual for dose preparation of Luxturna
For Healthcare Professionals
Surgical manual for the administration of Luxturna
Are you a healthcare professional?
Are you a healthcare professional?
Skip to main content